Cite
HARVARD Citation
Shih, Y. et al. (2019). Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet. 6 (8), pp. e398-e408. [Online].